Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform and Announces Introduction of Multiple New Products
Biedermann Motech, the prominent innovator in next generation spinal and extremity implant systems and procedural solutions, today announced the market introduction of several additions to its MOSS!MODULARITY™ platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019799867/en/
MOSS!MODULARITY Injection Screw
MOSS!MODULARITY encompasses a broad range of products and technologies for spinal surgery based around the concept of providing an advanced modular workflow for posterior stabilization and deformity correction. The modular workflow allows surgeons to place the headless bone screw shafts as a first step, without the tulip heads attached, and offers several advantages over working with traditional pre-assembled pedicle screws, e.g.:
- Improved visualisation and access to the surgical working space;
- Precise decompression, decortication and osteotomies without any interference with polyaxial tulip heads;
- Increased surgical versatility, as surgeons can choose between different types of modular screw shafts and various tulip heads to be added to the screw shafts in-situ as and when required.
Breaking new ground, Biedermann Motech will now introduce the MOSS!MODULARITY Injection Screw to selective markets outside the U.S. Fenestrated injection pedicle screws for spinal surgery, which Biedermann Motech has been pioneering since 2003, enable the injection of bone cement through the screw to enhance fixation in compromised bone1. The new injection screw workflow allows surgeons to insert the headless screw shaft directly into the bone, using the injection adaptor as the screw inserter, and then seamlessly inject bone cement before attaching the modular tulip heads to the screw shaft. The MOSS!MODULARITY Injection Screw workflow features proprietary technology licensed from intellectual property powerhouse and recognized innovation leader Biedermann Technologies GmbH & Co. KG and will be the first of its kind worldwide.
Simultaneously, Biedermann Motech will launch the next generation of its DELTA XS ® Retractor System for advanced Transforaminal Lumbar Interbody Fusion (“TLIF”) surgery. The DELTA XS 2.0 Retractor System has been specifically developed to combine the advantages of a screw shank based retractor with the benefits of the MOSS!MODULARITY workflow and can be used in a variety of surgical techniques and approaches, from open to less invasive, microsurgical TLIF surgery.
The MOSS!MODULARITY Injection Screw and the DELTA XS 2.0 Retractor System are fully compatible with the MOSS 100 Modular Pedicle Screw System, the MOSS VRS System and the MOSS VRS MIS System for advanced posterior fixation and correction and will further strengthen these platforms for specialized spinal surgery.
Biedermann Motech will showcase the worldwide first MOSS!MODULARITY Injection Screw and the DELTA XS 2.0 Retractor System at the upcoming Eurospine Meeting in Copenhagen, Denmark.
ABOUT BIEDERMANN MOTECH & BIEDERMANN TECHNOLOGIES
Biedermann is a mid-sized, family-owned group of companies, whose roots go back to 1916. Biedermann researches, develops, manufactures, and distributes high-end implant systems in collaboration with healthcare professionals, technology partners, scientific institutions, and specialized companies with the goal of achieving improved clinical outcomes. It is also owner and guardian of a substantial patent and technology portfolio for specialized orthopedic markets. For the last 30 years, Biedermann has successfully licensed numerous patents and related technologies to several key players in the orthopedic and neurosurgical field and established multiple new golden standards for spinal technologies.
For more information, please visit:
www.biedermann.com and www.biedermann-technologies.com
1 J Orthop Traumatol. 2011 Nov 8;12(4):193–199; Int J Spine Surg. 2021 Feb 26;15(1):113–118.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251019799867/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lazard Appoints Edouard Panié as Managing Director and Co-Head of European Financial Sponsors Coverage20.10.2025 08:00:00 CEST | Press release
Lazard, Inc. (NYSE: LAZ) today announced the appointment of Edouard Panié as Managing Director and Co-Head of the European Financial Sponsors Coverage. He will report to Klaus H. Hessberger, Global Co-Head and Head of Europe for Lazard’s Financial Sponsors Group, to further strengthen the firm’s presence and partnerships with financial sponsors across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019307537/en/ Edouard Panié Mr. Panié joins from Goldman Sachs, where he was a Managing Director for nearly two decades, advising on more than 60 landmark M&A, debt, and equity transactions for leading alternative asset managers in private equity, growth equity, and infrastructure, as well as entrepreneurs, families, and corporates. “Private capital is playing an increasingly pivotal role in shaping industries and driving growth. Edouard’s extensive experience and relationships will strengthen Lazard’s ability to pro
Lone Star Announces Sale of Xella to Holcim20.10.2025 06:40:00 CEST | Press release
Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund X, LP of a binding agreement to sell Xella Group (“Xella”), a leading provider of walling solutions, to Holcim, the leading partner for sustainable construction. The transaction values Xella at approximately €1.85 billion. Headquartered in Duisburg, Germany, Xella is a European provider of efficient and sustainable walling solutions for the entire house shell, operating brands such as Ytong, Silka, Hebel and Multipor. The company employs more than 4,000 team members. In partnership with Lone Star, Xella has taken significant strides in recent years to optimize its offering by strategically focusing the business on walling solutions, while also enhancing its commercial and digital capabilities. Under Lone Star’s stewardship, Xella has also continued to progress its sustainability initiatives. Today, the business stands as a market leader in its sector with a strong reputation for a people-first c
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom